Jeremy Jones
Research Subjects
Research Interests
Jeremy Jones has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Kathleen Campbell Garwood
Department of Decision and System Sciences, Saint Joseph’s University, Philadelphia, PA 19131, USA
2 shared publications - Kunhong Xiao
Department of Biomedical Engineering, College of Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA
2 shared publications - Kyla Frenia
Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15260, USA
2 shared publications - Leanne T. Labriola
Pittsburgh Research Institute, Sewickley, PA 15143, USA
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (9) , 866
Comparative Evaluation of Traditional and Emerging Glycemic Biomarkers in Diabetes
Diabetes mellitus is a worldwide metabolic disorder that can be debilitating to many if uncontrolled. Biomarkers, such as hemoglobin A1C and glycated albumin, are central to the effort to control diabetes. These each have their own advantages and disadvantages, and there is much ongoing research into development of improved biomarkers and biomarker measurement methods. Continuous glucose monitoring is also widely used to closely monitor diabetes in patients today. Increasingly, however, there has been research focusing on the use of biomarkers in alternative mediums, such as tear fluid or saliva. This review efficiently summarizes the current biomarkers used clinically today, their advantages and disadvantages, and the biomarkers on the horizon that could advance how diabetes is treated in the future.
- 26 August 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (9) , 866
Open AccessComparative Evaluation of Traditional and Emerging Glycemic Biomarkers in Diabetes
Diabetes mellitus is a worldwide metabolic disorder that can be debilitating to many if uncontrolled. Biomarkers, such as hemoglobin A1C and glycated albumin, are central to the effort to control diabetes. These each have their own advantages and disadvantages, and there is much ongoing research into development of improved biomarkers and biomarker measurement methods. Continuous glucose monitoring is also widely used to closely monitor diabetes in patients today. Increasingly, however, there has been research focusing on the use of biomarkers in alternative mediums, such as tear fluid or saliva. This review efficiently summarizes the current biomarkers used clinically today, their advantages and disadvantages, and the biomarkers on the horizon that could advance how diabetes is treated in the future.
- Open Access
- 12 August 2026
- Published by MDPI AG in Preprints.org
Comparative Evaluation of Traditional and Emerging Glycemic Biomarkers in Diabetes
Diabetes mellitus is a worldwide metabolic disorder that can be debilitating to many if uncontrolled. Biomarkers, such as hemoglobin A1C and glycated albumin, are central to the effort to control diabetes. These each have their own advantages and disadvantages, and there is much ongoing research into development of improved biomarkers and biomarker measurement methods. Continuous glucose monitoring is also widely used to closely monitor diabetes in patients today. Increasing, however, there has been research into use of biomarkers in alternative mediums, such as tear fluid or saliva. This review efficiently summarizes the current biomarkers used clinically today, their advantages and disadvantages, as well as the biomarkers on the horizon that could advance how diabetes is treated in the future.
- 12 August 2026
- Published by MDPI AG in Preprints.org
Open AccessComparative Evaluation of Traditional and Emerging Glycemic Biomarkers in Diabetes
Diabetes mellitus is a worldwide metabolic disorder that can be debilitating to many if uncontrolled. Biomarkers, such as hemoglobin A1C and glycated albumin, are central to the effort to control diabetes. These each have their own advantages and disadvantages, and there is much ongoing research into development of improved biomarkers and biomarker measurement methods. Continuous glucose monitoring is also widely used to closely monitor diabetes in patients today. Increasing, however, there has been research into use of biomarkers in alternative mediums, such as tear fluid or saliva. This review efficiently summarizes the current biomarkers used clinically today, their advantages and disadvantages, as well as the biomarkers on the horizon that could advance how diabetes is treated in the future.